Testing for tumor drug resistance in the age of molecular medicine. A contribution to the Debate Round-Table on phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice

Autoren

T Efferth

DOI

10.1038/sj.leu.2401551

eISSN

1476-5551

ISSN

0887-6924

Ausgabe der Veröffentlichung

10

Zeitschrift

Leukemia

Sprache

en

Online publication date

1999

Paginierung

1627 - 1629

Datum der Veröffentlichung

1999

Status

Published

Herausgeber

Springer Science and Business Media LLC

Herausgeber URL

http://dx.doi.org/10.1038/sj.leu.2401551

Datum der Datenerfassung

2022

Titel

Testing for tumor drug resistance in the age of molecular medicine. A contribution to the Debate Round-Table on phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice

Ausgabe der Zeitschrift

13

Data source: Crossref

Abstract

The detection of multidrug resistance (MDR) in clinical hospital practice represents an important strategy to combat clinical tumor drug resistance. Predicting the response of tumors to cytostatic drugs is of prognostic value. The 'Debate Round-Table on Phenotypic and Genotypic Analyses of Multidrug Resistance (MDR) in Clinical Hospital Practice' was launched in 1997 to address specific questions on this topic. The results published thus far are a rich source to learn about the promises and pitfalls of methods, eg surrogate and functional tests and protein or mRNA expression assays as well. In the present paper, some requirements are discussed for applications of drug resistance testing in clinical routine diagnostics. To improve the detection of low-level resistance, established methodologies may be strengthened with respect to: (1) standardization of sample handling, antibodies, PCR primers, and detection reagents; (2) standardization of protocols and far reaching automation in performance and evaluation of results to ensure high quality control criteria. Sophisticated new techniques will feature: (1) high-throughput analyses for the 'horizontal screening' of single drug resistance genes in large numbers of patient samples at economically fair costs; (2) 'vertical screening' of a large number of resistance mechanisms operating upstream or downstream of the actual drug-target interaction sites, in order to detect more complex and multifaceted genotypes and phenotypes of multidrug resistance.

Addresses

Institute for Clinical and Molecular Virology, University of Erlangen-Nürnberg, Schlossgarten 4, 91054 Erlangen, Germany.

Autoren

T Efferth
T Efferth

DOI

10.1038/sj.leu.2401551

eISSN

1476-5551

Externe Identifier

PubMed Identifier: 10516766

Open access

false

ISSN

0887-6924

Ausgabe der Veröffentlichung

10

Zeitschrift

Leukemia

Schlüsselwörter

Humans
Polymerase Chain Reaction
Drug Resistance, Multiple
Drug Resistance, Neoplasm
Genotype
Phenotype
Hospitals

Sprache

eng

Medium

Print

Paginierung

1627 - 1629

Datum der Veröffentlichung

1999

Status

Published

Datum der Datenerfassung

1999

Titel

Testing for tumor drug resistance in the age of molecular medicine. A contribution to the Debate Round-Table on Phenotypic and Genotypic Analyses of Multidrug Resistance (MDR) in Clinical Hospital Practice.

Sub types

Clinical Conference
Journal Article

Ausgabe der Zeitschrift

13

Data source: Europe PubMed Central

Abstract

The detection of multidrug resistance (MDR) in clinical hospital practice represents an important strategy to combat clinical tumor drug resistance. Predicting the response of tumors to cytostatic drugs is of prognostic value. The 'Debate Round-Table on Phenotypic and Genotypic Analyses of Multidrug Resistance (MDR) in Clinical Hospital Practice' was launched in 1997 to address specific questions on this topic. The results published thus far are a rich source to learn about the promises and pitfalls of methods, eg surrogate and functional tests and protein or mRNA expression assays as well. In the present paper, some requirements are discussed for applications of drug resistance testing in clinical routine diagnostics. To improve the detection of low-level resistance, established methodologies may be strengthened with respect to: (1) standardization of sample handling, antibodies, PCR primers, and detection reagents; (2) standardization of protocols and far reaching automation in performance and evaluation of results to ensure high quality control criteria. Sophisticated new techniques will feature: (1) high-throughput analyses for the 'horizontal screening' of single drug resistance genes in large numbers of patient samples at economically fair costs; (2) 'vertical screening' of a large number of resistance mechanisms operating upstream or downstream of the actual drug-target interaction sites, in order to detect more complex and multifaceted genotypes and phenotypes of multidrug resistance.

Autoren

T Efferth

Autoren-URL

https://www.ncbi.nlm.nih.gov/pubmed/10516766

DOI

10.1038/sj.leu.2401551

ISSN

0887-6924

Ausgabe der Veröffentlichung

10

Zeitschrift

Leukemia

Schlüsselwörter

Drug Resistance, Multiple
Drug Resistance, Neoplasm
Genotype
Hospitals
Humans
Phenotype
Polymerase Chain Reaction

Sprache

eng

Country

England

Paginierung

1627 - 1629

Datum der Veröffentlichung

1999

Status

Published

Datum, an dem der Datensatz öffentlich gemacht wurde

1999

Titel

Testing for tumor drug resistance in the age of molecular medicine. A contribution to the Debate Round-Table on Phenotypic and Genotypic Analyses of Multidrug Resistance (MDR) in Clinical Hospital Practice.

Sub types

Clinical Conference
Journal Article

Ausgabe der Zeitschrift

13

Data source: PubMed

Testing for tumor drug resistance in the age of molecular medicine. A contribution to the Debate Round-Table on phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice

Tools